Soteira
Stage
Acquired | AcquiredTotal Raised
$22.87MAbout Soteira
Soteira is a global medical device company with a mission to deliver advanced technologies for the treatment of vertebral compression fractures. The company offers a platform of products which allow the physician to tailor treatment to each individual patient. On July 8, 2012, Soteira was acquired by Globus Medical. The terms of the transaction were not disclosed.
Missing: Soteira's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Soteira's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Soteira Patents
Soteira has filed 3 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
9/30/2008 | 1/24/2012 | Orthopedic surgical procedures, Rare diseases, Bone fractures, Implants (medicine), Skeletal system | Grant |
Application Date | 9/30/2008 |
|---|---|
Grant Date | 1/24/2012 |
Title | |
Related Topics | Orthopedic surgical procedures, Rare diseases, Bone fractures, Implants (medicine), Skeletal system |
Status | Grant |
Latest Soteira News
Jun 14, 2021
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Soteira Frequently Asked Questions (FAQ)
Where is Soteira's headquarters?
Soteira's headquarters is located at 14 Tech Circle, Natick.
What is Soteira's latest funding round?
Soteira's latest funding round is Acquired.
How much did Soteira raise?
Soteira raised a total of $22.87M.
Who are the investors of Soteira?
Investors of Soteira include Globus Medical, HLM Venture Partners, Spray Venture Partners, Delphi Ventures, Trinity Ventures and 7 more.
Who are Soteira's competitors?
Competitors of Soteira include NeoChord, JenaValve, Itamar Medical, SynCardia Systems, Concentric Medical and 11 more.
Compare Soteira to Competitors
JenaValve develops, manufactures, and markets transcatheter aortic valve implantation systems (TAVI) to treat patients suffering from aortic valve disease. The company's transapical aortic valve system is CE-marked and currently marketed in Europe and other markets worldwide. The company was founded in 2006 and is based in Irvine, California.
CoAptus is developing a catheter device to seal up heart defects.
FocalCool is a medical device company. The company's goal is to develop technology that aims to reduce tissue damage from heart attacks and strokes. Using a special catheter system the company can apply rapid localized cooling to internal organs. The FocalCool team is made up of a Rowan University engineering professor, two engineers (one is a Rowan engineering graduate), and several Rowan engineering students.
Satiety, Inc. is a medical device company focused on the development of less invasive devices for the treatment of obesity. Obesity is a global health problem, affecting 70 million people in the U.S. and 300 million worldwide, and growth of which is causing increases in obesity-related diseases such as diabetes, high blood pressure and cardiovascular disease. Obesity surgery has been shown to be the only long-term effective means of weight loss for morbidly obese patients. Satiety's first product, the TOGA System, enables physicians to perform a procedure similar to traditional restrictive obesity surgeries, but without surgical incisions. In this procedure, the TOGA System devices are inserted transorally (through the mouth) and are used to reduce the capacity of the stomach to give patients a feeling of fullness after a small meal. The procedure is intended to be safer and easier for patients to tolerate than conventional obesity surgery. Safety and effectiveness of the TOGA System are currently being evaluated in a multi-center U.S. Study and the system is not available for sale in the United States.
CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.
NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.